title: Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens.
abstract: Chlamydia pneumoniae has been demonstrated in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS). Interferon-beta (IFN-beta) has favorable effects on the clinical course of MS. We investigated whether the beneficial effects of IFN-beta in MS may involve its role in regulating nitric oxide (NO) and interleukin-12 (IL-12) in macrophages, as these immune modulators form part of the innate immune response to intracellular pathogens, such as C. pneumoniae. Murine macrophages in cultures exposed to elementary body antigens or recombinant major outer membrane protein (rMOMP) of C. pneumoniae demonstrate a significant increase in NO as well as production of IL-12/p40 in culture supernatants compared with basal levels. Addition of murine IFN-beta increased NO activity in murine macrophages cultured with chlamydial antigens. Addition of neutralizing anti-IFN-beta antibody prevented the NO increase. In contrast to its effect on inducible NO synthase (iNOS), IFN-beta reduced induction of IL-12/p40 following culture with either elementary body antigens or rMOMP. Inhibition was reversed with anti-IFN-beta antibody. If C. pneumoniae infection is responsible for the inflammatory response in the pathogenesis of MS, the beneficial effects of IFN-beta in MS may be due to its enhancing intracellular NO activity while inhibiting secretion of the proinflammatory cytokine, IL-12.
authors.affiliation: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
authors.forename: S Y
authors.initials: SY
authors.lastname: Yao
authors.forename: A
authors.initials: A
authors.lastname: Ljunggren-Rose
authors.forename: C W
authors.initials: CW
authors.lastname: Stratton
authors.forename: W M
authors.initials: WM
authors.lastname: Mitchell
authors.forename: S
authors.initials: S
authors.lastname: Sriram
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology* / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins; D015153:Blotting, Western; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016899:Interferon-beta / Q000494:pharmacology*; D018664:Interleukin-12 / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D008565:Membrane Proteins / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D013154:Spleen / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D018664:Interleukin-12; D009569:Nitric Oxide; D016899:Interferon-beta; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse